ReviewDrugs2013
Simeprevir: first global approval.
Review in Drugs, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 46 citations in OpenAlex.
- Unraveling the therapeutic landscape of approved non-peptide macrocycles.Acta pharmaceutica Sinica. B · 2025Review
- Phosphoinositide kinases in cancer: from molecular mechanisms to therapeutic opportunities.Nature reviews. Cancer · 2025Review
- Interference of small compounds and MgScientific reports · 2024Article
- Observational
- Simeprevir restores the anti-Staphylococcus activity of polymyxins.AMB Express · 2023Article
- Deciphering the molecular and cellular atlas of immune cells in septic patients with different bacterial infections.Journal of translational medicine · 2023Review
- Mental Illness in Adults With HIV and HCV Infection: Indian Health Service, 2001-2020.American journal of preventive medicine · 2022Article
- Progress, evolving therapeutic/diagnostic approaches, and challenges in the management of hepatitis C virus infections.Archives of virology · 2022Review
- Fusion assays for screening of fusion inhibitors targeting SARS-CoV-2 entry and syncytia formation.Frontiers in pharmacology · 2022Article
- Observational
- Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection.Addictive disorders & their treatment · 2017Article
- Review
- Role of Marine Natural Products in the Genesis of Antiviral Agents.Chemical reviews · 2015Review
- New era for management of chronic hepatitis C virus using direct antiviral agents: A review.Journal of advanced research · 2015Review
- Hepatitis C virus antibody positivity and predictors among previously undiagnosed adult primary care outpatients: cross-sectional analysis of a multisite retrospective cohort study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015Article
- Treatment of chronic hepatitis C in patients with HIV/HCV coinfection.World journal of virology · 2015Review
- Review
- Simeprevir with peginterferon and ribavirin induced interstitial pneumonitis: first case report.World journal of gastroenterology · 2015Article
- The current state and future prospects of chronic hepatitis C virus infection treatment.Current infectious disease reports · 2014Article
- HCV genome-wide genetic analyses in context of disease progression and hepatocellular carcinoma.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Simeprevir (Sovriad(TM)) is a new direct-acting antiviral drug and a second-generation small-molecule NS3/4A serine protease inhibitor developed by Janssen and Medivir for the oral treatment of adults with genotype 1 and/or genotype 4 chronic hepatitis C virus (HCV) infection (chronic hepatitis C). Simeprevir antiviral activity is achieved by its non-covalent binding to HCV protease, with a fast association and slow dissociation rate. The capsule formulation is approved in Japan and Canada for use in combination with pegylated interferon (peginterferon) and ribavirin for genotype 1 chronic hepatitis C, and has been filed for approval in the US in this indication. In addition, the capsule formulation has been filed for approval in the EU for use in combination with peginterferon and ribavirin for genotype 1 and 4 chronic hepatitis C. Phase III trials of the capsule formulation of simeprevir are underway in several other regions, including China. In the pivotal phase III trials, simeprevir was administered once daily for 12 weeks in combination with peginterferon and ribavirin for 24 or 48 weeks. This article summarizes the milestones in the development of simeprevir leading to this first approval for chronic hepatitis C.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.